ArticleNature communications2023
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 51 citations in OpenAlex.
- Fusion gene heterogeneity and kinase enrichment in high-grade serous carcinomas.Neoplasia (New York, N.Y.) · 2026Article
- Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure.British journal of cancer · 2026Article
- Chemotherapy induces an IL1β-dependent neutrophil recruitment and activation that promote chemoresistance in metastatic ovarian cancer.Journal for immunotherapy of cancer · 2026Article
- Tilting the balance of life and death: navigating DNA replication stress in cancer therapy.Experimental & molecular medicine · 2026Review
- Pan-Cancer Analysis of NOP2 Reveals Its Prognostic Relevance and Association With the Tumor Immune Microenvironment.World journal of oncology · 2026Article
- Rethinking ovarian cancer III: the past decade and future directions.Nature reviews. Cancer · 2026Review
- Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.NPJ precision oncology · 2026Article
- DNA Copy Number Profiling in Extracellular Vesicles as Clinical Biomarkers of High-Grade Serous Ovarian Carcinoma.Journal of extracellular vesicles · 2026Article
- Identification of actionable targets using DEPArray-based sorting of pure carcinoma and stromal populations from formalin-fixed paraffin-embedded tissues followed by shallow whole-genome sequencing.The Journal of pathology · 2026Article
- Multimodal AI in high-grade serous ovarian cancer: integrated prediction and clinical decision-making.Frontiers in oncology · 2026Review
- Uncovering ShuangZi Powder's Anti-Ovarian Cancer Mechanism: A Systems Biology and Experimental Approach.Combinatorial chemistry & high throughput screening · 2026Article
- Integrative Genomic and Functional Analysis Reveals NF1 Loss as a Modifier of DNA Damage and Replication Stress Responses in Ovarian Cancer.Human mutation · 2026Article
- Genomic alterations linked to recurrence risk in high-grade serous ovarian cancer revealed by deep targeted sequencing.Scientific reports · 2025Article
- Genomic complexity and evolution of high-grade serous ovarian cancer treated with platinum-based chemotherapy: advancing precision oncology beyond BRCA1/BRCA2.Journal of ovarian research · 2025Article
- Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer.Cancer discovery · 2025Article
- Lightweight CNN efficiently discriminates ovarian cancer cells from a tumor microenvironment via holographic imaging flow cytometry.Biomedical optics express · 2025Article
- Article
- Post-translational modifications in ovarian cancer: implications for immunotherapy: a mini-review.Journal of ovarian research · 2025Review
- Coordinated protein modules define DNA damage responses to carboplatin at single-cell resolution in human ovarian carcinoma models.Cell reports. Medicine · 2025Article
- Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control.Cancer research · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
23 authors at 13 institutions in 2 countries.
Funding
Abstract
The drivers of recurrence and resistance in ovarian high grade serous carcinoma remain unclear. We investigate the acquisition of resistance by collecting tumour biopsies from a cohort of 276 women with relapsed ovarian high grade serous carcinoma in the BriTROC-1 study. Panel sequencing shows close concordance between diagnosis and relapse, with only four discordant cases. There is also very strong concordance in copy number between diagnosis and relapse, with no significant difference in purity, ploidy or focal somatic copy number alterations, even when stratified by platinum sensitivity or prior chemotherapy lines. Copy number signatures are strongly correlated with immune cell infiltration, whilst diagnosis samples from patients with primary platinum resistance have increased rates of CCNE1 and KRAS amplification and copy number signature 1 exposure. Our data show that the ovarian high grade serous carcinoma genome is remarkably stable between diagnosis and relapse and acquired chemotherapy resistance does not select for common copy number drivers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.